Media coverage about MannKind (NASDAQ:MNKD) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MannKind earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.8210590750664 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern’s analysis:
- MannKind (MNKD) Earns Buy Rating from HC Wainwright (americanbankingnews.com)
- Investor’s Alert (Technicals Data Analysis) – MannKind Corporation (NASDAQ: MNKD) (stockspen.com)
- MannKind Corporation (NASDAQ:MNKD) – P/E Ratio in Focus (nasdaqjournal.com)
- Analysts’ Review under Consideration: Mannkind Corporation (MNKD) and Pacific Biosciences (PACB) (postregistrar.com)
- MannKind (MNKD) Downgraded to Strong Sell at BidaskClub (americanbankingnews.com)
NASDAQ MNKD traded up $0.19 on Thursday, hitting $2.38. 2,043,482 shares of the company were exchanged, compared to its average volume of 3,610,605. The company has a market cap of $269.39, a price-to-earnings ratio of -2.05 and a beta of 2.91. The company has a quick ratio of 0.62, a current ratio of 0.65 and a debt-to-equity ratio of -0.48. MannKind has a 1-year low of $0.67 and a 1-year high of $6.96.
A number of brokerages recently issued reports on MNKD. BidaskClub raised shares of MannKind from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Zacks Investment Research upgraded shares of MannKind from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Thursday, March 29th. S&P Equity Research reduced their target price on shares of MannKind from $3.49 to $2.77 in a research note on Thursday, January 25th. Finally, Maxim Group restated a “hold” rating on shares of MannKind in a research note on Tuesday, January 30th. Five research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company’s stock. MannKind presently has an average rating of “Sell” and a consensus price target of $1.88.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.